Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.

被引：3
|
作者：
Peng, Zhi
Zhang, Xiaotian
Liang, Han
Zheng, Zhichao
Wang, Zhenning
Liu, Hao
Hu, Jiankun
Sun, Yihong
Zhang, Yanqiao
Yan, Han
Tong, Lin
Xu, Jiahui
Xie, Jessica
Ji, Jiafu
Shen, Lin
机构：
[1] Peking Univ, Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res,Dept Gastro, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[3] Liaoning Canc Hosp, Shenyang, Peoples R China
[4] China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang, Peoples R China
[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[6] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Precis Med Gastrointestina, Guangzhou, Guangdong, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[8] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[10] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[11] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
[12] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-424-6846-174; 261-492-2769; 283-2511; 261-566-148-2649; 281-318-430; 283-424-6846-5514; 261-566-9690; 6; 4; 3; 2; 291; 1791; 1854; 1704; 239; 92; 5; 38092-22447;
D O I：
10.1200/JCO.2024.42.3_suppl.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: A prospective, multicenter, open-label, single-arm phase II study
    Long, B.
    Zhou, H.
    Wei, D.
    Yang, T.
    Chai, N.
    Yu, Z.
    Yang, H.
    Guan, X.
    Zhang, W.
    Chen, S.
    Zhou, L.
    Jiang, X.
    Shi, W.
    Huang, Z.
    Zhu, J.
    Luo, C.
    Mao, J.
    Dong, C.
    Jiang, Z.
    Zhao, X.
    Zhao, D.
    Jiao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S70 - S71
  • [22] A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Alarcon Rozas, Ashley
    de Matos Neto, Joao Nunes
    Caleffi, Maira
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Gutierrez, Carolina
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina M.
    Solca, Flavio
    Osborne, C. Kent
    CLINICAL BREAST CANCER, 2015, 15 (02) : 101 - 109
  • [23] A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Gutierrez, Martin
    Sigal, Darren
    Berth, Kevin
    Kuehn, Adam
    Colerangle, John
    Koppisetti, Sharmila
    He, Shawn
    van der Touw, William
    Hariri, Robert
    Awadalla, Mark S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS478 - TPS478
  • [24] Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study.
    Wang, Feng
    Liu, Tian Shu
    Yuan, Xianglin
    Gu, Kangsheng
    Yuan, Ying
    Deng, Yanhong
    Xu, Jian-Ming
    Bai, Yu-Xian
    Wang, Ying
    Liao, Wangjun
    Zhang, He-Long
    Bi, Feng
    Wang, Bang-Mao
    Zhuang, Zhixiang
    Luo, Huiyan
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
    Klempner, Samuel J.
    Shitara, Kohei
    Sison, Allan
    Scott, Jennifer
    Wishengrad, Dana
    Ronayne, Jack
    Rhee, Joon
    Mitra, Siddhartha
    Nuyten, Dimitry S. A.
    Janjigian, Yelena Y.
    Wainberg, Zev A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] An open-label phase 2 study of lenvatinib plus pembrolizumab in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
    Kawazoe, Akihito
    Wakabayashi, Masashi
    Furuya, Hideki
    Sato, Akihiro
    Sakamoto, Naoya
    Kuwata, Takeshi
    Kinoshita, Takahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
    Li, Z.
    Ji, J.
    Bu, Z.
    Wang, Y.
    Wu, Z.
    Nie, P.
    Li, W-L.
    Li, C.
    You, J.
    Hu, W.
    Zhang, Y.
    Chen, L.
    Zhao, P.
    Li, G.
    Li, Y.
    Zhuang, J.
    Shen, J.
    Feng, D.
    Fang, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S911 - S911
  • [29] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study
    Babu, K. Govind
    Prabhash, Kumar
    Vaid, Ashok K.
    Sirohi, Bhawna
    Diwakar, Ravi B.
    Rao, Raghunadha
    Kar, Madhuchanda
    Malhotra, Hemant
    Nag, Shona
    Goswami, Chanchal
    Raina, Vinod
    Mohan, Ravi
    ONCOTARGETS AND THERAPY, 2014, 7 : 1051 - 1060
12345